AUTHOR INDEX

Ades, T.B., 290
Anderson, R.W., 109

Bailey, L.J., 154
Beck, S.L., 11
Birenbaum, L.K., 50
Bookbinder, M., 3, 36
Boyle, D.A., 109
Brown, H.G., 305

Cherry, C., 167
Christensen, A., 86
Condosta, D., 223
Cooke, L., 71
Coons, M., 223
Cover, M., 290
Crawford, K., 143

Daly, N.R., 265
Davenport-Ennis, N., 290
Dean, G.E., 20
DeVita, V.T. Jr., 252
Door, A., 207

Fischer, M., 193
Frank-Stromborg, M., 85, 128
Fulton, J.S., 28

Ganschow, J.R., 99, 128
Grant, M., 1, 71

Hinds, P.S., 50
Hubbard, S.M., 252
Hunt, J.M., 79

Kamin, D.Y., 265

Lajeunesse, J.D., 109

Martin, V.R., 165, 174
Mayer, D.K., 239, 241, 252
McPhail, J.T., 28
Meier, E., 105
Middleton, G.J., 28
Moore, P., 276
Mortenson, L.E., 297

O'Keefe, M.E., 143

Parsons, S.K., 241
Pedrosa, A.M., 50
Pedrosa, F., 50
Penne, K., 66
Porter, S., 200

Quinn, L.K., 60

Rieger, P.T., 276
Rutledge, D.N., 1, 3

Schulmeister, L., 109
Smith, E.L., 36
Spinelli, A., 184
Sportsman, S., 149
Stahl, C., 20
Stovall, E., 290
Swenson, C.J., 135

Tabano, M., 223
Temple, S.V., 231
Teytelman, Y., 121

Vacchiano, S.A., 167
Valadez, A.M., 149

Whedon, M.B., 36
Wilson, B.J., 44

Zuk, S.M., 60

SUBJECT INDEX

ACCC (Association of Community Cancer Centers), 282, 286, 300
Access to health care, barriers to, 259–263
Acquired immunodeficiency syndrome advocacy, 290–292
ACS (American Cancer Society), 292–293, 305
Advertising, tobacco-related, 246–247
Advocacy
  AIDS, 290–292
  American Cancer Society and, 292–293
  Cancer Leadership Council and, 294–295
  current/emerging issues, 288
  current ONS activities, 277–288
  future of, 295–296
  initiatives for, 296–297
  National Coalition for Cancer Survivorship and, 293–295
  ONS, history of, 277, 278
African Americans, 307
Age
  cancer incidence and, 253
  politics/policy and, 308
AIDS advocacy, 290–292
American Cancer Society (ACS), 292–293, 305
American Nurses Association Code of Ethics, 277
American Society for Therapeutic Radiology and Oncology (ASTRO), 287, 298
American Society of Clinical Oncology (ASCO), 286, 298, 299, 300
"America's Oncology Nurses: Advocates in Action," 282
Aortic aneurysm, smoking and, 244
APON (Association of Pediatric Oncology Nurses), 286
Arent Fox, 278
ASCO (American Society of Clinical Oncology), 286, 298, 299, 300
Asian-Americans, 307
Association of Community Cancer Centers (ACCC), 282, 286, 300
Association of Pediatric Oncology Nurses (APON), 286
ASTRO (American Society for Therapeutic Radiology and Oncology), 287, 298
Atheroselerosis, smoking and, 244

Bladder cancer, smoking and, 244
Bush Administration, 271

Cancer advisory groups, 272–274
Cancer Leadership Council (CLC), 294–295, 298
Cancer policy. *See also specific health policy issues*
  issues, for Congress/governmental agencies, 242–243
  ONS involvement in, 277
  population issues, 307–309
  state governments and, 272
Centers for Disease Control and Prevention (CDC), 272
Centers for Medicare and Medicaid Services (CMS), 271–272, 301
Cerebrovascular disease, smoking and, 244
Chronic obstructive pulmonary disease, smoking and, 244
Cigarette excise tax, 249, 261
Cigarette labeling, 246–247
Cigarette smoking. *See* Smoking
CLC (Cancer Leadership Council), 294–295, 298
Clinical Journal of Oncology Nursing, 282
Clinical trials
  low participation in, 260
  safety during, 260
Clinton Administration, 248, 272, 301
CMS (Centers for Medicare and Medicaid Services), 271–272, 301
Coalitions. *See also specific cancer coalitions*
  evolution of, 297–298
  examples of, 298
  future of, 303–304
  political development of, 300–302
Congress
  health policy issues for, 242–243
  tobacco-related bills, 248
Coronary heart disease, smoking and, 244

Daschle, Senator Tom, 283
Deaths, tobacco-related, 243, 244, 261–262

"The Denver Principles," 291
Department of Defense, 269–270
Diagnostic Related Groups (DRGs), 299, 301
Diseases, smoking-related, 244, 248
DRGs (Diagnostic Related Groups), 299, 301

Economic issues
  burden of cancer, 263
  provider, 299–300
  smoking-related, 243
Education, for ONS members, 281–283
Elderly, politics/policy and, 308
EONS (European Oncology Nursing Society), 287
Esophageal cancer, smoking and, 244
European Oncology Nursing Society (EONS), 287

FDA. *See* Food and Drug Administration
Federal Commerce Commission Fairness Doctrine, 243
Federal Trade Commission (FTC), 246–247
Food, Drug, and Cosmetic Act, 247
Food and Drug Administration (FDA)
  authority over tobacco products, 247
  drug approval process, 259
  regulatory mandate, 270
FTC (Federal Trade Commission), 246–247
Funding, research
  challenges/recommendations for, 255, 258
  National Institutes of Health and, 254, 266–268
  special interest groups and, 302–303

Government. *See also specific government agencies*
  health policy issues for, 242–243
  role in health care, 241–242

Health Care Financing Administration (HCFA), 301
Health care insurance, inadequate coverage, 259–260
Health care planning, 262
Health care policy. *See* Cancer policy
Health care professionals
  myths about being politically active, 283, 284
  shortages of, 258
Health care system
  challenges/recommendations for cancer care, 255–263
  components for cancer care, 255
Health Policy Tool Kit, 282
Health Resources and Services Administration (HRSA), 269
Health status, smoking and, 244
HHS (U.S. Department of Health and Human Services), 265–266
Hispanic Americans, 307
Human immunodeficiency virus (HIV), 291–292

Incidence of cancer, 252–253, 261–262
International Society of Nurses in Cancer Care (ISNCC), 287
International Union Against Cancer (UICC), 287
ISNCC (International Society of Nurses in Cancer Care), 287

Kidney cancer, smoking and, 244

Labeling, of cigarettes, 246–247
Laryngeal cancer, smoking and, 244
Legal settlements, tobacco-related, 249–250
Legislation. *See also specific legislation*
  advocacy efforts and, 295
  tobacco control, 245, 247
Longest model, 242
Lung cancer, smoking and, 244

Mayer, Deborah K., 277
Medicaid
  governmental authority for, 241–242
  reimbursement fraud and, 270–271
Medical records privacy, 271
Medicare
  as federal program, 241–242
  reimbursement fraud, 270–271
  reimbursement limits, 271–272
Minority population, politics/policy and, 307
Mortality rates, 252–253, 254

National Bioethics Advisory Commission, 260
National Cancer Act of 1971, 253, 254, 265, 297
National Cancer Institute (NCI)
  bypass budget, 253–254, 267
  cancer advisory groups, 273–274
  "Extraordinary Opportunities for Investment," 267, 268
  grants, 270
  National Cancer Act and, 253
  research budget, 274
  research funding and, 254, 266–267
National Cancer Legislation Advisory Committee (NCLAC)
  cancer battle plan, 254–255, 305–306
  challenges/recommendations for cancer care, 255–263, 305
National Cancer Program
  challenges/recommendations for, 255–263
  Legislation Advisory Committee members, 264
  legislative history, 253–254
National Cancer Screening Initiative, 261
National Coalition for Cancer Research (NCCR), 298
National Coalition for Cancer Survivorship (NCCS), 293–294
National Dialogue on Cancer (NDC), 298, 303, 305, 309
National Health Institutes (NIH), 260
National Institute for Environmental Health Science (NIEHS), 259, 269
National Institute on Aging, 268
National Institute on Nursing Research, 268–269
National Institutes of Health (NIH)
  cancer programs, 268–270
  funding of research and, 266–268
  National Cancer Institute. *See* National Cancer Institute
  organization of, 268
National Patient Advocacy Foundation, 302
Native American health care, 262
NCCR (National Coalition for Cancer Research), 298
NCCS (National Coalition for Cancer Survivorship), 293–294
NCI. *See* National Cancer Institute
NCLAC. *See* National Cancer Legislation Advisory Committee
NDC (National Dialogue on Cancer), 298, 303, 305, 309
"Negative rights," 241
NIEHS (National Institute for Environmental Health Science), 259, 269
NIH. *See* National Institutes of Health
Nurse in Washington Internship Program (NIWI), 280, 283
Nutrition, cancer-related deaths and, 262

Office of Human Research Protections, 260
"Off-label" drug use, 27, 270, 299
Oncology Nursing Forum, 282
Oncology nursing practice, scope of, 274–275
Oncology Nursing Society (ONS), 276, 287
  advocacy agenda, 279, 280
  history of, 277, 278
  lobbying efforts, 283–285
  member education, 281–283
  online legislative action center, 280–281
  organizational structure of, 277–278, 280–281
  professional partnerships, 285–288
  resources of, 277–278, 280–281
  volunteer members, 280
Onco-politics
  early years of, 298–299
  evolution of, 297–298

ONS. *See* Oncology Nursing Society
Oral cancer, smoking and, 244

PAF (Patient Advocate Foundation), 296
Pain Relief Promotion Act, 283
Pancreatic cancer, smoking and, 244
Patient Advocate Foundation (PAF), 296
Peptic ulcer disease, smoking and, 244
Policy. *See* Cancer policy
Politics, population issues and, 307–309
Population, politics/policy and, 307–309
"Positive rights," 241
President, cancer advisory groups and, 272–274
PRGs (Progress Review Groups), 267–268
Professional organizations
  evolution of political involvement, 297–298
  fiscal restraints, 288
Progress against cancer, 305–306
Progress Review Groups (PRGs), 267–268
Public Law 244, 253
Public policymaking model, 242

Quality of care, barriers to, 259–263

Reimbursement
  fraud, 270–271
  for quality care, 299–300
Reporting requirements, 262–263
Research
  agenda, 302–303
  funding. *See* Funding, research
  grants, 299
  obstacles for, 255, 258–259
Research community, initial involvement in policy/politics, 299
Routine care costs, 260–261
Ryan White CARE Act, 291–292

Screenings
  Medicare-supported, 261
  rates among elderly, 261
Second-hand smoke, protection from, 243
SHPL (State Health Policy Liaison), 280
Smoking
  adverse health effects of, 243, 244, 246
  prevalence of, 243
  tobacco control efforts and, 243, 246–249
Smoking cessation programs, 261
Special interest groups, 302–303
State governments, cancer policy and, 272
State Health Policy Liaison (SHPL), 280
Survival rates, 252, 306

Taxes, on tobacco/tobacco-related products, 249, 261
"The Framework Convention on Tobacco Control," 248
Tobacco control efforts, 243, 246–249
Tobacco industry, 245–246, 247–248
Tobacco-related cancers, 306
Tobacco settlements, 249–250
Tobacco tax, 249, 261
"Translational centers," 258

UICC (International Union Against Cancer), 287
United States population, politics/policy and, 307–309
U.S. Department of Health and Human Services (HHS), 265–266

White house, cancer advisory groups and, 272–274